Fnu Shahid, Ph.D. PMP

Come visit me at the poster session of BioTechX tomorrow in Philly! My poster is called "Identification and Annotation of Publicly Available Single Cell RNA-sequencing Data". Rancho BioSciences #biotechxphilly #biotechx 

12

This comprehensive peer-reviewed set of more than 600 definitions covers topics of interest for the biopharmaceutical and gene therapy subjects of genetics, therapeutics, drug development, clinical medicine, and the analytical science tools used for characterization of drugs. This glossary serves as a helpful reference to both novice and advanced scientists, engineers, and business executives involved with biopharmaceuticals and gene therapy technologies. Online sources of information for topics covered in this guide are also included for additional insights.

12

Come join us as a Postdoctoral Fellow to study #Ubiquitin, #Autophagy, #Biochemistry, and #Proteomics at the Sloan Kettering Institute in New York. Postdoctoral Fellow in Cell Biology, Biochemistry or Proteomics (New York). Sloan Kettering Institute See the full job description on jobRxiv: https://lnkd.in/du7qbW9w #biochemistry #cell_biology #proteomics #proteostasis #ubiquitin

9

Impact of biosimilars on biologic drug development pipelines.

4

Drug discovery method integrates time-resolved X-rays to examine protein shapes Small molecule drug discovery methods seek to identify candidates that interact with protein targets, but often overlook how drug binding impacts protein structure over time. Researchers led by Chris Brosey, Ph.D., and John Tainer, Ph.D., developed a novel drug discovery method that combines classic fragment screening with a technique for mapping protein structures, called time-resolved, high throughput small-angle X-ray scattering (TR-HT-SAXS). They tested this method on the mitochondrial protein AIF by monitoring how a library of small molecules alters AIF structural states over time. In the resulting dataset, researchers identified specific chemical fragments that cause two AIF proteins to bind and activate. Follow-up biochemical and structural experiments validated these findings, suggesting this drug discovery workflow is capable of identifying small molecules that bind and modify protein structure in desired ways. This approach could lead to higher specificity in chemical hits and the ability to target natural rate-limiting steps in cells. Nature Chemical Biology https://rdcu.be/dHnHe

29

2 Comments

Congratulations to Carrie Hoefer, PhD, MBA, associate dean of undergraduate and online pharmacy programs at #UBuffalo SPPS, on receiving the STRIPE Double Helix Award from the American Society of Pharmacovigilance (ASP)! STRIPE, which stands for Standardizing Laboratory Practices in Pharmacogenomics, is a continuing forum where public and private sector members collaborate to integrate personalized medicine into standard healthcare practices. The STRIPE Double Helix Awards celebrate individuals and organizations who have made exceptional contributions to the field of pharmacogenomics. Hoefer was recognized with the award for Excellence in Advancing Pharmacogenomics through Collaboration: honoring leaders who have driven significant advancements in pharmacogenomics by fostering collaboration across disciplines, organizations, and sectors. Their work has helped bridge gaps in science, practice, and policy, accelerating the adoption of pharmacogenomics. Hoefer received the award at the inaugural STRIPE Annual Meeting and Consensus Workshop, held from October 23-25 in Rockville, MD. The meeting brought together the pharmacogenomics community to develop consensus standards and strategies for advancing precision medicine and underscored the importance of collaboration and scientific achievement in expanding the reach and effectiveness of pharmacogenomics testing. Read more at bit.ly/4hodSQy #Pharmacogenomics #PGx #STRIPEcc #Pharmacovigilance #PharmaceuticalSciences #PharmacySchool

57

3 Comments

My talk at Columbia University titled "Challenges and opportunities in drug development in the age of precision medicine" https://lnkd.in/dPxmECtM If you don't want to watch a 13-minute video (sorry, no TikTok version), here is a TLDR: - Use longitudinal models of disease, not discreet response metrics - Compute the probability of the effect (Bayes!), not p-values - If you use external controls, make sure to identify a causal estimand - Run adaptive trials (both early and later)

23

1 Comment

Don't miss our poster presentations at Discovery on Target in Boston, MA! 📃 "Identification and characterization of small molecules inhibiting RNA targets: miRNA" 🏷 Session A, poster A39 📆 October 1st to 2nd a.m. 👩🏼‍🔬 Paola C., PhD, Director Alliance Management Abstract: RNA plays a key role in transcription and translation: gene regulation, proliferation, apoptosis, and development. The biological function is linked to the unique secondary and tertiary structures. Many diseases are associated with dysregulation of RNA functions, so there is a growing interest in RNAs as drug targets for novel therapies or targeting undruggable proteins. The most used modalities are antisense oligonucleotides (ASOs), CRISPR gene editing, and more recently small molecules. [...] Discover more about our approach that demonstrates a miRNA targeting platform that could be applied to other oncogenic miRNA targets: https://lnkd.in/edM4ecJj For more questions and details, come and meet our team at our booth 508! #DrugDiscovery #Biophysics #RNA #SPR #microRNA #DiscoveryOnTarget #BostonDOT24

47

[Science Note] 🔬Cancer cells hijack macrophages to metastasis🧬 Recent research into cancer metastasis shows that cancer cells hijack immune cells, particularly macrophages, to promote metastasis. We've compiled key papers that delve into how macrophages contribute to cancer spread and immune evasion. Explore them here: https://lnkd.in/d_-uU9gR #Macrophage #CellDeath #CancerResearch #Apoptosis

8

Really looking forward to discussing #resume myths today with Clinical Research Management (CRM) Network This is a free webinar folks. Don't miss it! #CRA #jobseekers

6

🚀 Exciting findings in the realm of ADCs and in the key role of payloads to develop effective treatments against cancer!  The latest study conducted by Chen et al. dives deep into the effectiveness of alternative payload strategies in treating lung cancer, shedding light on a potentially game-changing approach. Traditionally, much emphasis has been placed on novel targeting in the development of antibody-drug conjugates (ADCs). However, the research suggests that simply swapping out payloads could offer a higher probability of success compared to pursuing novel targeting. In this investigation involving 79 lung cancer patients, with a majority being HER2-positive, they found that maintaining the same payload while switching antibody formats yielded marginal benefits, with an overall response rate (ORR) of approximately 5.3%. However, the story took a significant turn when they explored the impact of swapping payloads. The ORR skyrocketed to an impressive 22.6% with this approach. What's more intriguing is the observation that in patients with advanced disease progression, a switch to a different payload led to remarkable outcomes. A staggering 41.2% ORR was noted in these patients, with some experiencing durable responses lasting more than 6 months. A compelling case study further illustrates this point, comparing trastuzumab deruxtecan (T-Dxd) with disitamab vedotin (RC48). The difference in progression-free survival 2 (PFS2) between the two treatments was striking, with T-Dxd demonstrating a PFS2 of 5.37 months compared to 3.30 months for RC48. Furthermore, the overall survival (OS) with T-Dxd extended to an impressive 50.6 months, in stark contrast to 20.2 months with RC48. These findings underscore the potential of alternative payload strategies in enhancing the efficacy of cancer therapies, particularly in patients with advanced disease. By focusing on payloads selection, we could pave the way for more effective treatment options and improved patient outcomes. Elikya Therapeutics, a Landmark BioVentures company, is focused on the development of next Generation of ADCs using its First-in-Class toxic payload, with a unique mode of able to address tumor and its microenvironment in parallel, and with a long-standing memory immune response. Elikya's unique approach focuses also on the development of Precision Conjugates: considering that new ADCs shall be designed on the comprehensive mechanistic properties of the payload (payload centric design). #ADCs #toxicpayloads #Precisionsconjugates. #CancerResearch #Innovation #TherapeuticAdvancements

14

Attention : Postdoctoral Fellow - HIV Assembly, Release, and Maturation Organization National Cancer Institute, Frederick, MD Scientific focus area Virology About the position A postdoctoral position is currently available in Dr. Eric Freed's research program at NCI-Frederick, USA. A postdoctoral position is currently available in a research program focused on a variety of key aspects of HIV-1 assembly, release, and maturation. Of particular interest are the interplay between viral and host factors in HIV-1 replication and the mechanism by which the viral envelope glycoproteins are incorporated into virions. Recent studies have been aimed at defining the cellular pathways and host factors involved in envelope glycoprotein incorporation and identifying inhibitors of virus maturation. Mechanisms of HIV-1 drug resistance are also under investigation, and studies are underway to define the target and mechanism of action of novel HIV-1 maturation inhibitors and to identify host factors that restrict HIV-1 replication. ... Application Link : https://lnkd.in/g2UyaEHK

1

SysBio(89a) Beyond Associations: how to Find True Drug Targets with Causal Inference in observational data? Part I. If you're familiar with drug discovery, you've likely noticed a familiar scene: an exciting new target is often accompanied by a Kaplan-Meier (K-M) plot, showing how patient outcomes differ based on the target gene expression levels from clinical trial data. Many newbies in drug discover may think that it is attempting to generalize this simple approach systematically to find many more drug targets than we thought: If we can use any large patient Omics data (like TCGA) to automatically generate K-M plots for every gene, could it be a straightforward way to find new drug targets if you see statistically significant prognosis separation? This is a common mistake—relying solely on observation data to identify promising drug targets without considering other crucial causal factors can lead to misleading conclusions. 💡 The Key Insight: Understanding Biological Data Types To find valuable drug targets, it's crucial to first understand a foundational concept in data science: the difference between Controlled Experiments and Observational Data—each type demands distinct analytical methods for meaningful insights. 1️⃣ Controlled Experiments: These are studies involving cell lines or animal models or well-designed randomized clinical trials, where the conditions are tightly regulated except for the gene or other factors being tested. In such settings, classical statistical methods like differential expression analysis, linear regression or more complicated association-based neuron network models are effective, as confounding variables effects are minimized by well-controlled experiment design. 2️⃣ Observational Data: In contrast, observational data, such as patient data from diverse populations (e.g., TCGA or any real-world data), is inherently complex, with many hidden causal factors like age, gender, disease stage, and genetic factors etc. influencing disease prognosis and drug treatment outcomes. Direct associations here can be misleading without proper handling of these unknown causal factors. For example, if we study the effect of exercise (like biking) on cholesterol levels without adjusting for age, we might wrongly associate the exercise time with increasing cholesterol level (see Figure), while in fact age is a hidden factor influencing the result. Similarly, in human patients omics data, huge number of hidden factors can obscure true gene-prognosis relationships. #Drugdiscovery #CausalInference #causalAI

11

📢 New Insight in Gene Therapy Researchers at the RCCS San Raffaele Scientific Institute in Milan have discovered that hematopoietic stem cells (HSCs) adapt their lineage commitment in response to the specific genetic disease they’re treating. This means that during gene therapy, HSCs shift their development to better address disease-specific needs. This discovery offers promising directions for refining HSC-GT protocols and improving long-term patient outcomes. Exciting times ahead for #GeneTherapy and personalized medicine! #GeneTherapy #StemCells #Hematology #Biotechnology #MedicalResearch #HealthcareInnovation

7

I am so excited to be heading to PEGS-Boston this week! I am looking forward to presenting my poster, "Investigating Factors Impacting TLR7 Immunostimulatory ADC pharmacokinetics and pharmacodynamics."

27

Nucleus is the all-in-one DNA test, capturing DNA differences that influence your risk for common and rare diseases for the most comprehensive look yet into your health.

9